Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seng Gee Lim

Showing results (221-230 of 241) with videos related to

Pageof 25
Sort By:
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Journal of Viral Hepatitis|August 25, 2018
Findings from a large Asian chronic hepatitis C real-life studySeng Gee Lim, Wah Wah Phyo, Samir R Shah, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
The Lancet. Gastroenterology & Hepatology|December 18, 2018
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trialLai Wei, Seng Gee Lim, Qing Xie, et al.
Journal of Hepatology|February 29, 2024
Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunityBalakrishnan Chakrapani Narmada, Atefeh Khakpoor, Niranjan Shirgaonkar, et al.
The American Journal of Gastroenterology|December 12, 2025
Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B studyJie Li, Joanne Kimiko Liu, Angela Chau, et al.
The New England Journal of Medicine|May 28, 2026
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus InfectionJinlin Hou, Seng-Gee Lim, Maria Buti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 21, 2023
Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal StudyAngela Chau, Ming-Lun Yeh, Pei-Chien Tsai, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 24, 2020
Impact of metabolic risk factors on the severity and outcome of patients with alcohol-associated acute-on-chronic liver failureAjay Duseja, Arka De, Sunil Taneja, et al.
Pageof 25

Showing results (221-230 of 241) with videos related to

Sort By:
Pageof 25
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Journal of Viral Hepatitis|August 25, 2018
Findings from a large Asian chronic hepatitis C real-life studySeng Gee Lim, Wah Wah Phyo, Samir R Shah, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
The Lancet. Gastroenterology & Hepatology|December 18, 2018
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trialLai Wei, Seng Gee Lim, Qing Xie, et al.
Journal of Hepatology|February 29, 2024
Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunityBalakrishnan Chakrapani Narmada, Atefeh Khakpoor, Niranjan Shirgaonkar, et al.
The American Journal of Gastroenterology|December 12, 2025
Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B studyJie Li, Joanne Kimiko Liu, Angela Chau, et al.
The New England Journal of Medicine|May 28, 2026
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus InfectionJinlin Hou, Seng-Gee Lim, Maria Buti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 21, 2023
Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal StudyAngela Chau, Ming-Lun Yeh, Pei-Chien Tsai, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 24, 2020
Impact of metabolic risk factors on the severity and outcome of patients with alcohol-associated acute-on-chronic liver failureAjay Duseja, Arka De, Sunil Taneja, et al.
Pageof 25